535
edits
Changes
Created page with "200px|thumb|right|Logo of Team Sanbox == Joint Venture 2019 == Joint Venture is a team competing in Sensus 2019, its university is the Imperial College..."
[[File:sandbox.jpg|200px|thumb|right|Logo of Team Sanbox]]
== Joint Venture 2019 ==
Joint Venture is a team competing in Sensus 2019, its university is the Imperial College London. For Sensus 2019, Joint Venture investigated the possibilities for creating a biosensor which is able to measure the concentration of [[Adalimumab]]. The full TRD can be found [https://digital2019.sensus.org/storage/526/TRD---Team-Joint-Venture.pdf via this link]
== Method ==
Magnetic Microparticle Centrifugation
==Molecular Recognition ==
Our point-of-care system makes use of a magnetic microparticle centrifugation technique coupled with the char-acteristic bright red colour of AuNPs1 2to give an optical readout proportional to the concentration of ADL in thepatient’s plasma.
== Physical Transduction ==
A blood plasma sample with a high concentration of ADL will give the strongest coloured solution. Conversely, a blood plasma sample with a much lower concentration of ADL will give a near colourless supernatant. The intensity of the coloured solution is measured using a spectrophotometer.
== Cartridge ==
In order to minimise our environmental impact, oursensor has been designed to rely on modified clearacrylic slides, as can be seen in Appendix II. Theseare easily produced at low cost with a minimal envi-ronmental impact caused by mass development.
== Reader Instrument ==
Our biosensor’s screen is the main communication point for the patient, with our appADAacting as a tool touse alongside for tracking and management. There is a large, easy to use touch screen, housed in a sensor 20 by 14 by 10 cm in size.
== Joint Venture 2019 ==
Joint Venture is a team competing in Sensus 2019, its university is the Imperial College London. For Sensus 2019, Joint Venture investigated the possibilities for creating a biosensor which is able to measure the concentration of [[Adalimumab]]. The full TRD can be found [https://digital2019.sensus.org/storage/526/TRD---Team-Joint-Venture.pdf via this link]
== Method ==
Magnetic Microparticle Centrifugation
==Molecular Recognition ==
Our point-of-care system makes use of a magnetic microparticle centrifugation technique coupled with the char-acteristic bright red colour of AuNPs1 2to give an optical readout proportional to the concentration of ADL in thepatient’s plasma.
== Physical Transduction ==
A blood plasma sample with a high concentration of ADL will give the strongest coloured solution. Conversely, a blood plasma sample with a much lower concentration of ADL will give a near colourless supernatant. The intensity of the coloured solution is measured using a spectrophotometer.
== Cartridge ==
In order to minimise our environmental impact, oursensor has been designed to rely on modified clearacrylic slides, as can be seen in Appendix II. Theseare easily produced at low cost with a minimal envi-ronmental impact caused by mass development.
== Reader Instrument ==
Our biosensor’s screen is the main communication point for the patient, with our appADAacting as a tool touse alongside for tracking and management. There is a large, easy to use touch screen, housed in a sensor 20 by 14 by 10 cm in size.
